Want to see IBRX full AI Analyst Report?
Nogapendekin Alfa Inbakicept, N-803, Anktiva
Sepsis
Phase II
Not Yet Recruiting
NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis
Aug 21, 2026
―
Cisplatin, Nab-Paclitaxel, Nogapendekin Alfa Inbakicept, Had5-Hpv Vaccine, De-Intensified Imrt, Standard Of Care Imrt
Head And Neck Cancer, Oropharyngeal Squamous Cell Carcinoma, Hpv-Positive Oropharyngeal Squamous Cell Carcinoma
Phase II
Not Yet Recruiting
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
Jun 01, 2026
Bcg, Bcg Plus Anktiva
Nmibc
Phase III
Withdrawn
ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer
Apr 20, 2026
―
Nogapendekin Alfa-Inbakicept, Allogeneic Invariant Natural Killer T Cells, N-803, Alt-803, Anktiva
Sepsis, Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Lymphopenia / Immunoparalysis In Critically Ill Adults
Phase II
Withdrawn
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
Mar 13, 2026
―
N-803, Anktiva, Nogapendekin Alfa Inbakicept, Sotevtamab, Zabadinostat, Nab Paclitaxel / Gemcitabine
Pancreatic Cancer, Pancreatic Cancer Resectable
Phase I
Not Yet Recruiting
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
Nov 20, 2025
Pembrolizumab, Enfortumab Vedotin, Anktiva, Nogapendekin Alfa Inbakicept, N-803, Keytruda, Padcev
Bladder Cancer, Urothelial Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Phase I
Not Yet Recruiting
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
Oct 14, 2025
Nogapendekin Alfa Inbakicept, Agent-797
Sepsis, Community-Acquired Pneumonia (Cap), Lymphopenia, Acute Respiratory Distress Syndrome (Ards), Immunoparalysis
Phase III
Withdrawn
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
Sep 18, 2025
―
N-803
Long Covid
Phase II
Recruiting
A Study to Assess Anktiva in Patients With Long Covid-19.
Jul 30, 2025
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does ImmunityBio (IBRX) have in its pipeline
IBRX is currently developing the following drugs: Nogapendekin Alfa Inbakicept, N-803, Anktiva, Cisplatin, Nab-Paclitaxel, Nogapendekin Alfa Inbakicept, Had5-Hpv Vaccine, De-Intensified Imrt, Standard Of Care Imrt, Bcg, Bcg Plus Anktiva. These drug candidates are in various stages of clinical development as the company works toward FDA approval.